Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 5/20 | 0.74 |
| ▸ | CDK2 | P24941 | 1/20 | 0.74 |
| ▸ | TBK1 | Q9UHD2 | 16/20 | 0.73 |
| ▸ | MARK3 | P27448 | 3/20 | 0.73 |
| ▸ | MARK4 | Q96L34 | 3/20 | 0.73 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.73 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.63 |
| ▸ | TYK2 | P29597 | 2/20 | 0.63 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.63 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.63 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.63 |
| ▸ | BMPR2 | Q13873 | 2/20 | 0.63 |
| ▸ | STK16 | O75716 | 1/20 | 0.63 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.63 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.63 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.63 |
| ▸ | ULK1 | O75385 | 3/20 | 0.63 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.63 |
| ▸ | ULK2 | Q8IYT8 | 3/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865033 | 0.98 | PDPK1 (0.74) | PDPK1CDK2TBK1MARK3MARK4 | |
| SCHEMBL13897431 | 0.92 | PDPK1 (0.71) | PDPK1CDK2TBK1MARK3MARK4 | |
| SCHEMBL3867811 | 0.91 | ULK1 (0.76) | PDPK1CDK2TBK1MARK3MARK4 | |
| SCHEMBL13898170 | 0.91 | TBK1 (0.75) | PDPK1CDK2TBK1MARK3MARK4 | |
| SCHEMBL3863942 | 0.90 | PDPK1 (0.76) | PDPK1CDK2TBK1MARK3MARK4 | |
| SCHEMBL13898211 | 0.90 | PDPK1 (0.75) | PDPK1CDK2TBK1MARK3MARK4 | |
| SCHEMBL3865565 | 0.89 | PDPK1 (0.75) | PDPK1CDK2TBK1MARK3MARK4 | |
| SCHEMBL29915250 | 0.89 | PDPK1 (0.75) | PDPK1CDK2TBK1MARK3MARK4 | |
| SCHEMBL3867098 | 0.89 | PDPK1 (0.71) | PDPK1CDK2TBK1MARK3MARK4 | |
| SCHEMBL13898056 | 0.88 | PDPK1 (0.72) | PDPK1CDK2TBK1MARK3MARK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | claimed |
| EP-1565446-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-24 | — | — | EP | claimed |
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | claimed |
| WO-2004048343-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | WO | claimed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| EP-1565446-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-24 | — | — | EP | disclosed |
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | disclosed |
| WO-2004048343-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | DCK, PDPK1, DTYMK | PDPK1 2/4885CDK2 105/4885TBK1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.